Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine

[1]  R. Levy,et al.  Serotonin and catecholamines in the development and progression of heart valve diseases , 2017, Cardiovascular research.

[2]  C. Torp-Pedersen,et al.  Hyperprolactinemia and the Association with All-Cause Mortality and Cardiovascular Mortality , 2017, Hormone and Metabolic Research.

[3]  J. Henzen.  Publisher's note , 1979, Brain Research.

[4]  A. Colao,et al.  The safety of treatments for prolactinomas , 2016, Expert opinion on drug safety.

[5]  Sigrun Alba Johannesdottir Schmidt,et al.  The Danish National Patient Registry: a review of content, data quality, and research potential , 2015, Clinical epidemiology.

[6]  A. Pontecorvi,et al.  Hyperprolactinemia: pathophysiology and therapeutic approach , 2015, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[7]  R. Vasan,et al.  Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. , 2014, European heart journal.

[8]  Tejal Patel,et al.  Parkinson’s disease guidelines for pharmacists , 2014, Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC.

[9]  N. Ben-Jonathan,et al.  Minireview: Extrapituitary prolactin: an update on the distribution, regulation, and functions. , 2014, Molecular endocrinology.

[10]  W. Drake,et al.  A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. , 2014, The Journal of clinical endocrinology and metabolism.

[11]  J. Dieleman,et al.  Risk of Cardiac Valve Regurgitation with Dopamine Agonist use in Parkinson’s Disease and Hyperprolactinaemia , 2012, Drug Safety.

[12]  P. García-Pavía,et al.  No clinically significant valvular regurgitation in long‐term cabergoline treatment for prolactinoma , 2012, Clinical endocrinology.

[13]  S. Zacharieva,et al.  Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. , 2012, European journal of endocrinology.

[14]  H. Sørensen,et al.  Heart valve disease among patients with hyperprolactinemia: a nationwide population-based cohort study. , 2012, The Journal of clinical endocrinology and metabolism.

[15]  S. Yarman,et al.  Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas. , 2012, Neuro endocrinology letters.

[16]  C. Boguszewski,et al.  A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas , 2012, Pituitary.

[17]  Bryan L Roth,et al.  Serotonin receptors and heart valve disease--it was meant 2B. , 2011, Pharmacology & therapeutics.

[18]  C. Pedersen,et al.  The Danish Civil Registration System , 2011, Scandinavian journal of public health.

[19]  J. Hallas,et al.  The Danish National Prescription Registry , 2011, Scandinavian journal of public health.

[20]  Victor M Montori,et al.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[21]  Alfredo Berardelli,et al.  Early (Uncomplicated) Parkinson's Disease , 2010 .

[22]  A. Schapira,et al.  Drug-induced fibrotic valvular heart disease , 2009, The Lancet.

[23]  N. Sandu,et al.  Gender-related differences in pituitary adenomas. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[24]  Jeroen J. Bax,et al.  Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. , 2008, The Journal of clinical endocrinology and metabolism.

[25]  A. Andermann,et al.  Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. , 2008, Bulletin of the World Health Organization.

[26]  M. Schluchter,et al.  Prevalence of unsuspected and significant mitral and aortic regurgitation. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[27]  J. Gardin,et al.  Burden of valvular heart diseases: a population-based study , 2006, The Lancet.

[28]  S. Härtter,et al.  A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. , 2006, Clinical therapeutics.

[29]  F. Viallet,et al.  Fibrotic valvular heart disease subsequent to bromocriptine treatment. , 2002, Cardiology in review.

[30]  Jagmeet P. Singh,et al.  Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) , 1999, The American journal of cardiology.

[31]  A. Weyman,et al.  Prevalence of valvular regurgitation by Doppler echocardiography in patients with structurally normal hearts by two-dimensional echocardiography. , 1989, American heart journal.

[32]  Ja Wilson,et al.  Principles and practice of screening for disease , 1968 .